10-10-2013, 04:17 PM
Genentech’s drug to be used in the treatment of Breast cancer has been approved by FDA under its accelerated program for drug approval.
Drug: Perjeta (Pertuzumab)
To be used in the treatment of people with early stage breast cancer who are also HER-2 positive. The drug Perjeta is used as Neoadjuvant treatment in the patient before the patient is operated surgically for breast cancer treatment.
Combination used in the treatment of HER 2 (Human Epidermal Growth Factor Receptor 2) positive patients: Perjeta + Herceptin + Docetaxel chemotherapy.
The drug is approved by FDA based on the results from the Neoadjuvant study of Pertuzumab and Herceptin in an Early Regimen Evaluation which is a phase II study.
The drug is awaiting the data from the Phase III study which is called as APHINITY study to get full approval from FDA.
Function of the Drug Perjeta:
The HER 2 receptor is known to be found externally on most of the healthy cells. In case of cancerous cells this HER 2 receptors are found in abundance and these receptors are the main targets for the drug Perjeta. The growth of the tumor is enhanced by the binding of HER 2 receptor with HER 1, HER 3 or HER 4 receptor and the drug Perjeta obstructs this binding of receptors by attaching itself to the HER 2 receptor and this attachment is also known to trigger body’s immune system to function against the tumor cells. The drug used in combination with Herceptin is known to terminate the signaling pathways of HER receptors.
The expected side effects on the usage of the drug include cardiac problems, some allergic responses, fatigue, vomiting, change in taste and also known to have side effects on the fetus when used in pregnant women and the patients are asked to inform their doctors about any occurrence of side effects on taking the drug and there is also Genentech life line number available to provide assistance to the patients who are taking Perjeta.
Drug: Perjeta (Pertuzumab)
To be used in the treatment of people with early stage breast cancer who are also HER-2 positive. The drug Perjeta is used as Neoadjuvant treatment in the patient before the patient is operated surgically for breast cancer treatment.
Combination used in the treatment of HER 2 (Human Epidermal Growth Factor Receptor 2) positive patients: Perjeta + Herceptin + Docetaxel chemotherapy.
The drug is approved by FDA based on the results from the Neoadjuvant study of Pertuzumab and Herceptin in an Early Regimen Evaluation which is a phase II study.
The drug is awaiting the data from the Phase III study which is called as APHINITY study to get full approval from FDA.
Function of the Drug Perjeta:
The HER 2 receptor is known to be found externally on most of the healthy cells. In case of cancerous cells this HER 2 receptors are found in abundance and these receptors are the main targets for the drug Perjeta. The growth of the tumor is enhanced by the binding of HER 2 receptor with HER 1, HER 3 or HER 4 receptor and the drug Perjeta obstructs this binding of receptors by attaching itself to the HER 2 receptor and this attachment is also known to trigger body’s immune system to function against the tumor cells. The drug used in combination with Herceptin is known to terminate the signaling pathways of HER receptors.
The expected side effects on the usage of the drug include cardiac problems, some allergic responses, fatigue, vomiting, change in taste and also known to have side effects on the fetus when used in pregnant women and the patients are asked to inform their doctors about any occurrence of side effects on taking the drug and there is also Genentech life line number available to provide assistance to the patients who are taking Perjeta.
![[+]](https://www.biotechnologyforums.com/images/netpen-pro/collapse_collapsed.png)